{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:36:50Z","timestamp":1788536210908,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40290-026-00625-x","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:30:23Z","timestamp":1787196623000},"page":"357-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Empowering Medical Affairs Professionals in Their Critical Role in Integrated Evidence Generation Planning"],"prefix":"10.1007","volume":"40","author":[{"given":"Judith","family":"Nelissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cerise","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0357-3707","authenticated-orcid":false,"given":"Gary","family":"Male","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"625_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/cer-2017-0073","volume":"7","author":"MS Olson","year":"2018","unstructured":"Olson MS. Developing an integrated strategy for evidence generation. J Comp Eff Res. 2018;7:5\u20139.","journal-title":"J Comp Eff Res"},{"key":"625_CR2","unstructured":"Grueger N, Andre N, Vaidyanathan S. 2023. The future of integrated evidence planning in biopharma. Available from: https:\/\/www.bcg.com\/publications\/2023\/the-future-of-integrated-evidence-planning-in-biopharma. Accessed 4 Mar 2026."},{"key":"625_CR3","unstructured":"Amin P, Nam S, P\u00e9rez L, Smith J. Integrated evidence generation: a paradigm shift in biopharma. 2021. Available from: https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/integrated-evidence-generation-a-paradigm-shift-in-biopharma. Accessed 4 Mar 2026."},{"key":"625_CR4","first-page":"3","volume-title":"Medical affairs. The roles, value and practice of medical affairs in the biopharmaceutical and medical technology industries","author":"K Shepard","year":"2025","unstructured":"Shepard K, Kremer C, Winter-Sperry R, du Plessis D, Piliero P. What is medical affairs. In: Medical affairs. The roles, value and practice of medical affairs in the biopharmaceutical and medical technology industries. 1st ed. Boca Raton (FL): CRC Press; 2025. p. 3\u201314.","edition":"1st ed"},{"key":"625_CR5","doi-asserted-by":"publisher","unstructured":"Fujii R, Nouri M, Khan M, Fleisinger L, Pugh J, Male G, Panayi A. Integrated evidence generation planning: effective medical affairs leadership in an evolving landscape. Pharm Med. 2026. https:\/\/doi.org\/10.1007\/s40290-026-00620-2.","DOI":"10.1007\/s40290-026-00620-2"},{"key":"625_CR6","unstructured":"White R, Schiller S, Low E, Wadsworth AC. Unlocking evidence impact: aligning IEGPs and strategic publications for smarter communication, 2025. Available from: https:\/\/www.ismpp-newsletter.com\/2025\/10\/28\/iegp-strat-pubs\/. Accessed 4 Mar 2026."},{"key":"625_CR7","unstructured":"European Medicines Agency. Reflection paper on patient experience data. 2025. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-patient-experience-data_en.pdf. Accessed 4 Mar 2026."},{"key":"625_CR8","unstructured":"US Food and Drug Administration. FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. 2025. Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical. Accessed 4 Mar 2026."},{"key":"625_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13561-014-0012-8","volume":"4","author":"V Ivandic","year":"2014","unstructured":"Ivandic V. Requirements for benefit assessment in Germany and England: overview and comparison. Health Econ Rev. 2014;4:12.","journal-title":"Health Econ Rev."},{"key":"625_CR10","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462321000167","volume":"37","author":"N Cook","year":"2021","unstructured":"Cook N, Livingstone H, Dickson J, et al. Development of an international template to support patient submissions in health technology assessments. Int J Technol Assess Health Care. 2021;37:e50.","journal-title":"Int J Technol Assess Health Care"},{"key":"625_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.107990","volume":"240","author":"A Ataya","year":"2025","unstructured":"Ataya A, Plomaritis N, Rhee M, Perinkulam Sathyanarayanan S, Robinson B. A patient journey map for people living with autoimmune pulmonary alveolar proteinosis. Respir Med. 2025;240:107990.","journal-title":"Respir Med"},{"key":"625_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70206","volume":"18","author":"NR Naylor","year":"2025","unstructured":"Naylor NR, Hummel N, de Moor C, Kadambi A. Potential meets practicality: AI\u2019s current impact on the evidence generation and synthesis pipeline in health economics. Clin Trans Sci. 2025;18:e70206.","journal-title":"Clin Trans Sci."},{"key":"625_CR13","unstructured":"European Medicines Agency. The use of artificial intelligence (AI) in the medicinal product lifecycle. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf. Accessed 4 Mar 2026."},{"key":"625_CR14","unstructured":"National Institute for Health and Care Excellence. Use of AI in evidence generation: NICE Position Statement. 2024. Available from: https:\/\/www.nice.org.uk\/about\/what-we-do\/our-research-work\/use-of-ai-in-evidence-generation--nice-position-statement. Accessed 4 Mar 2026."}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00625-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00625-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00625-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:22:59Z","timestamp":1788495779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-026-00625-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00625-x","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"28 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Judith Nelissen is an employee of Astellas Pharma Europe BV. Angela Williams is an employee of Kyowa Kirin International. Cerise James is an employee of Tilghman James Group LLC. Gary Male is an employee of Oxford PharmaGenesis Ltd. The opinions presented in this article are solely of the authors and not those of the companies they are employed by.","order":1,"name":"Ethics","label":"Conflicts of interest\/Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the outline and subsequent drafts of this manuscript. All authors contributed to the drafting and critical review of the manuscript content and approved the final manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}